April 26, 2022
Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate
Valneva SE and Pfizer Inc. have reported positive Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Valneva
April 14, 2022
Valneva’s Inactivated Covid-19 Vaccine Gets CMA in UK
The Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom has granted Conditional Marketing Authorization (CMA) for Valneva’s inactivated whole-virus COVID-19 vaccine candidate, VLA2001, for primary immunization in adults 18 to 50 years of age.
March 24, 2022
Valneva Reports Loss in Y2021, Has Big Plans for 2022
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, has reported €73 million net loss in its audited consolidated financial results for the year ending December 31, 2021 and provided corporate updates.
March 11, 2022
Valneva Provides Regulatory Update on its COVID-19 Vaccine Candidate
Valneva SE has provided an update on the regulatory review of its inactivated, COVID-19 vaccine candidate, VLA2001, by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
March 8, 2022
Valneva Successfully Completes Pivotal Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate
Valneva SE has announced successful completion of the Phase 3 pivotal trial of its single-shot chikungunya vaccine candidate, VLA1553.
March 1, 2022
Kingdom of Bahrain OKs Valneva’s Inactivated COVID-19 Vaccine
National Health Regulatory Authority (NHRA) of the Kingdom of Bahrain has granted emergency use authorization for Valneva’s inactivated, adjuvanted COVID-19…
February 25, 2022
Valneva Receives Initial CHMP Assessment of its Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, has announced that the Committee for Medicinal Products for…
February 21, 2022
Valneva awarded up to £20 M by Scottish Enterprise to advance vaccine development
Valneva’s subsidiary Valneva Scotland has been awarded research and development funding of up to £20 million by Scottish Enterprise. The…
January 5, 2017
Valneva, Merck in new animal vaccines deal (U.S.&Canada)
Valneva has given Merck in United States and Canada rights to use its EB66 technology to research new veterinary vaccines.
December 16, 2016
Valneva closes private placement in connection with EUR15.2m investment by MVM
French vaccines developer Valneva has closed the share issuance in connection with MVM Life Science Partners LLP`s investment in the…